Traction is not revenue. It is evidence.

What founders get wrong about traction

Most founders treat traction as a single scalar that goes up and to the right, usually revenue, sometimes users. So the pre-revenue founder concludes she has none, and the founder with early revenue concludes he has plenty. Both are reading the wrong instrument.

An investor is not buying your current number. They are underwriting a specific risk, and which risk depends entirely on your stage. At pre-seed, the risk is usually "does anyone actually want this badly enough to change their behavior." At seed, it shifts to "can you reliably get this in front of people and keep them." By Series A, it is "does this retain and expand like a real product, and can you spend a dollar to make more than a dollar." Traction is whatever evidence shrinks the particular risk you are being judged on right now.

This is why revenue can be weak traction and a waitlist can be strong traction. Eighteen thousand dollars from one dying channel with churning logos does not shrink the seed-stage risk. It arguably grows it, because now there is a number that is not improving. Forty procurement conversations with three unsolicited LOIs shrink the pre-seed risk a lot. The number that looks more impressive on a slide is the weaker evidence.

The founder's job is not to produce the most impressive metric. It is to identify the risk the investor is underwriting and present the cleanest available evidence that the risk is going down.

The framework: five kinds of evidence

Traction evidence falls into five categories. They tend to mature in roughly this order, and at any given stage one or two of them carry the weight while the rest are supporting.

Demand. Evidence that the problem is real and acute. Inbound interest, waitlist growth without paid acquisition, LOIs, design partners who chase you, the rate at which people forward your signup link. This is the evidence that matters most before you have a working product.

Usage. Evidence that people actually use the thing once they have it. Activation rate, frequency, depth of use, the share of signups who reach the core action. Usage separates "interesting demo" from "thing people open on a Tuesday."

Retention. Evidence that usage persists. Cohort curves that flatten instead of decaying to zero, logo retention, the answer to "what happens in month three." Retention is the single hardest kind of evidence to fake and the one investors trust most, because it is the closest proxy for whether you have built something durable.

Willingness to pay. Evidence that the value converts to money. Conversion from free to paid, contract sizes, price increases that stick, the length of the sales cycle, whether buyers expand. Revenue lives here, but so do unsigned-but-committed LOIs and "we have budget for this next quarter."

Distribution. Evidence that you can reliably get in front of buyers and that it gets cheaper or easier over time. A repeatable channel, a CAC that is stable or falling, referral loops, a content engine that compounds. This is what turns a product people want into a company that grows.

The mistake is presenting all five flatly, or presenting the one you happen to have the best number for. The move is to know which one your stage is being judged on, lead with your strongest honest evidence there, and be straight about the rest.

A concrete example: the same company, three stages

Take a vertical AI tool for radiology clinics. Watch which evidence does the work at each stage.

Pre-seed. No product, a clickable prototype. The risk is demand. The strong evidence is not "we project $2M ARR by year two." It is "we ran twenty-two clinics through the prototype, fourteen asked when they can buy, and two radiology directors offered to be design partners and gave us their data to test on." That shrinks the demand risk. The financial projection shrinks nothing.

Seed. Product is live, eight paying clinics. The risk is usage and early retention. Strong evidence: "of eight clinics, seven log in daily, average six reads per clinician per day, and the two clinics from our three-month cohort are both still active and have added seats." Weak evidence at this stage: the total revenue number alone, which is too small to mean anything on its own.

Series A. Forty clinics, $90K MRR. The risk is whether this retains and whether distribution repeats. Strong evidence: "net revenue retention is 118%, our gross logo churn is under 5% annually, and 60% of new clinics now come from referrals from existing ones at a third of the CAC of our outbound." Now the revenue number matters, but only because retention and distribution evidence make it believable that the number keeps growing.

Same company. The "traction" that wins each meeting is a different kind of evidence, matched to a different risk. A founder who leads with revenue at pre-seed looks naive. A founder who leads with a waitlist at Series A looks like they are hiding the retention problem.

The artifact: a traction evidence matrix

Build this once, keep it current, and walk into any investor meeting knowing exactly which cell to lead with. Columns are the five evidence types. Rows are your stage. In each relevant cell, write the single strongest honest fact you have, and mark its strength.

Three rules for filling it in honestly:

First, one fact per cell, the strongest real one. Not a list, not a projection. If the best you have is a projection, the honest entry is "None" and you say so.

Second, mark strength conservatively. A single retained cohort of two logos is "Thin," not "Strong," and an investor will trust you more for saying so. Marking thin evidence as strong is the fastest way to lose a room, because the next question exposes it.

Third, use the matrix to decide what to say, not just what to track. Before a meeting, identify the investor's stage risk, find the cell that shrinks it, and lead there. Let the "Thin" and "None" cells become your honest "here is what we are proving next quarter."

A founder who can point at the matrix and say "you are underwriting retention, here is exactly what I have on retention, it is thin but real, and here is the experiment that turns it from thin to strong in ninety days" is doing the investor's risk assessment for them. That founder reads as someone who understands their own company, which is itself a form of traction.

Where this breaks down in practice

The matrix is easy to draw and hard to keep honest, because the evidence is scattered. The demand signals live in your inbox and in call notes. The usage and retention facts live in a product analytics tool or a spreadsheet nobody updates. The willingness-to-pay evidence is buried in deal threads and CRM notes. The investor reactions, which tell you which risk each fund actually cares about, live in your memory and decay within a week.

So the real failure is not that founders lack evidence. It is that the evidence is never assembled in one place at the moment they need it, and they walk into the meeting reaching for the one number they can remember, usually revenue. The strongest fact you have about demand might be a line a procurement manager said on a call six weeks ago that you never wrote down.

Where RoundOS fits

RoundOS pulls the round's raw material into one place: call notes, customer and investor emails, meeting transcripts, the spreadsheet of conversations you have been keeping. From that, the evidence for each cell of the matrix stops being something you reconstruct from memory the night before a pitch. The LOI a director offered on a call, the seat a clinic added in month three, the reaction a specific partner had to your retention slide. Those become entries you can find, attach to the right evidence type, and bring into meeting prep, instead of facts that evaporate.

It also tracks which risk each investor keeps probing. When three funds in a row press on retention, that is a signal about what your stage is being judged on, and RoundOS surfaces it as a next move rather than leaving it as a vague feeling that the meetings keep going sideways in the same place.